Sun Yonglian, Chen Jonathan H, Fu Yangxin
The Department of Pathology, The University of Chicago, Chicago, Illinois 60637, USA.
Cell Mol Immunol. 2004 Feb;1(1):31-6.
CD137 (4-1BB), a member of the TNF receptor superfamily, is an inducible T cell costimulatory receptor primarily expressed on activated CD4+ and CD8+ T cells. Agonistic monoclonal antibodies (mAbs) against CD137 greatly enhance T cell-mediated immune responses against many types of tumors and viruses. Surprisingly, these agonists also showed therapeutic effects in several autoimmune diseases. These findings suggest that in different disease environments, CD137 engagement with agonist mAb in vivo can diametrically modulate immune response outcomes. Therefore, CD137 agonists represent a promising immunotherapeutic approach to a wide array of disparate immune disorders. However, CD137's potency in modulating immune response necessitates caution when targeting CD137 clinically.
CD137（4-1BB）是肿瘤坏死因子受体超家族的成员，是一种主要在活化的CD4+和CD8+T细胞上表达的诱导性T细胞共刺激受体。针对CD137的激动性单克隆抗体（mAb）可极大地增强T细胞介导的针对多种肿瘤和病毒的免疫反应。令人惊讶的是，这些激动剂在几种自身免疫性疾病中也显示出治疗效果。这些发现表明，在不同的疾病环境中，体内CD137与激动剂mAb的结合可截然调节免疫反应结果。因此，CD137激动剂代表了一种针对多种不同免疫疾病的有前景的免疫治疗方法。然而，CD137在调节免疫反应方面的效力使得在临床上靶向CD137时需要谨慎。
